Glytas 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glytas 80 is typically prescribed when diet, exercise, and weight reduction alone have not achieved adequate glycemic regulation. The medication aids in lowering both fasting and postprandial blood glucose levels, contributing to the prevention of long-term diabetic complications such as neuropathy, nephropathy, and retinopathy. It is essential to administer Glytas 80 with meals to reduce the risk of hypoglycemia, a common adverse effect characterized by symptoms such as dizziness, sweating, and palpitations. Dosage adjustments should be individualized based on patient response and glycemic monitoring. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and periodic assessment of hematological and hepatic parameters are recommended during therapy. Glytas 80 should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize potential risks.